|
1
|
Wu Y, Zhang J, Zhu R, Zhang H, Li D, Li H, Tang H, Chen L, Peng X, Xu X, Zhao K. Mechanistic Study of Novel Dipeptidyl Peptidase IV Inhibitory Peptides from Goat's Milk Based on Peptidomics and In Silico Analysis. Foods 2024; 13:1194. [PMID: 38672866 PMCID: PMC11049645 DOI: 10.3390/foods13081194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2024] [Revised: 04/01/2024] [Accepted: 04/05/2024] [Indexed: 04/28/2024] Open
Abstract
Two novel dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (YPF and LLLP) were discovered from goat milk protein by peptidomics, in silico analysis, and in vitro assessment. A total of 698 peptides (<23 AA) were successfully identified by LC-MS/MS from goat milk hydrolysates (hydrolyzed by papaian plus proteinase K). Then, 105 potential DPP-IV inhibitory peptides were screened using PeptideRanker, the ToxinPred tool, Libdock, iDPPIV-SCM, and sequence characteristics. After ADME, physicochemical property evaluation, and a literature search, 12 candidates were efficiently selected and synthesized in vitro for functional validation. Two peptides (YPF and LLLP) were found to exert relatively high in vitro chemical system (IC50 = 368.54 ± 12.97 μM and 213.99 ± 0.64 μM) and in situ (IC50 = 159.46 ± 17.40 μM and 154.96 ± 8.41 μM) DPP-IV inhibitory capacities, and their inhibitory mechanisms were further explored by molecular docking. Our study showed that the formation of strong non-bonding interactions with the core residues from the pocket of DPP-IV (such as ARG358, PHE357, GLU205, TYR662, TYR547, and TYR666) might primarily account for the DPP-IV inhibitory activity of two identified peptides. Overall, the two novel DPP-IV inhibitory peptides rapidly identified in this study can be used as functional food ingredients for the control of diabetes.
Collapse
Affiliation(s)
- Yulong Wu
- School of Public Health, Hangzhou Normal University, Hangzhou 311121, China; (Y.W.); (R.Z.)
- Institute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.Z.); (H.Z.); (D.L.); (H.L.); (H.T.); (L.C.)
| | - Jin Zhang
- Institute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.Z.); (H.Z.); (D.L.); (H.L.); (H.T.); (L.C.)
| | - Ruikai Zhu
- School of Public Health, Hangzhou Normal University, Hangzhou 311121, China; (Y.W.); (R.Z.)
- Institute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.Z.); (H.Z.); (D.L.); (H.L.); (H.T.); (L.C.)
| | - Hong Zhang
- Institute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.Z.); (H.Z.); (D.L.); (H.L.); (H.T.); (L.C.)
- College of Food Engineering and Nutritional Science, Shaanxi Normal University, Xi’an 710062, China
| | - Dapeng Li
- Institute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.Z.); (H.Z.); (D.L.); (H.L.); (H.T.); (L.C.)
- College of Life Science, Yantai University, Yantai 264005, China;
| | - Huanhuan Li
- Institute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.Z.); (H.Z.); (D.L.); (H.L.); (H.T.); (L.C.)
| | - Honggang Tang
- Institute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.Z.); (H.Z.); (D.L.); (H.L.); (H.T.); (L.C.)
| | - Lihong Chen
- Institute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.Z.); (H.Z.); (D.L.); (H.L.); (H.T.); (L.C.)
| | - Xinyan Peng
- College of Life Science, Yantai University, Yantai 264005, China;
| | - Xianrong Xu
- School of Public Health, Hangzhou Normal University, Hangzhou 311121, China; (Y.W.); (R.Z.)
| | - Ke Zhao
- Institute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.Z.); (H.Z.); (D.L.); (H.L.); (H.T.); (L.C.)
| |
Collapse
|
|
2
|
Hayashi T, Murayama H, Shinfuku Y, Taniguchi T, Tsumiyama I, Oyama N. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin. Expert Opin Pharmacother 2019; 21:121-130. [PMID: 31689132 DOI: 10.1080/14656566.2019.1685500] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Background: Vildagliptin is a dipeptidyl peptidase-4 inhibitor that reduces glycemia in patients with type 2 diabetes mellitus (T2DM). When approved in 2013, data on vildagliptin combined with >750 mg/day metformin in Japanese patients were limited. There is a need to confirm the safety and efficacy of vildagliptin in combination with oral antidiabetic drugs (OADs).Research design and methods: This 52-week post-marketing surveillance (PMS) observational study in Japanese T2DM patients evaluated the safety and efficacy of vildagliptin in combination with OADs including high-dose metformin or insulin but excluding combination with sulfonylureas alone.Results: During this survey of 3006 Japanese T2DM patients, 13.61% of patients experienced adverse events (AEs) and 2.20% reported a serious AE (SAE). The frequency of AEs/SAEs was similar when in combination with biguanides (12.93%/1.46%), metformin ≥1000 mg/day (12.92%/1.22%), metformin <1000 mg/day (12.62%/1.54%), thiazolidine derivatives (16.71%/2.86%), α-glucosidase inhibitors (13.18%/1.90%), rapid-acting insulin secretagogues (glinides) (20.41%/5.71%), or insulin (15.87%/2.47%). The mean ± SD changes from baseline at endpoint in glycated hemoglobin and fasting blood glucose were -0.76 ± 1.27% and -23.3 ± 57.3 mg/dL, respectively, and these changes were consistent, regardless of concomitant OAD.Conclusions: Long-term vildagliptin combination therapy is safe and effective in Japanese T2DM patients in real-world settings.
Collapse
Affiliation(s)
| | | | - Yohei Shinfuku
- Regulatory Office Japan, Novartis Pharma K.K., Tokyo, Japan
| | | | | | | |
Collapse
|
|
3
|
Chae H, You BH, Choi J, Chin Y, Kim H, Choi HS, Choi YH. Ginseng berry extract enhances metformin efficacy against obesity and hepatic steatosis in mice fed high-fat diet through increase of metformin uptake in liver. J Funct Foods 2019; 62:103551. [DOI: 10.1016/j.jff.2019.103551] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|